Latest News
Germany's Merck breaks ground on $321m biomanufacturing center
Germany's Merck breaks ground on $321m biomanufacturing center
Merck KGaA has begun construction on an 18,000 square-meter research center at its global headquarters in Darmstadt, Germany.
Deal-Making
Ferring Pharmaceuticals has picked CDMO SK pharmateco to commercially produce Adstiladrin, a bladder cancer gene therapy treatment.
Cellares will allocate multiple Cell Shuttles and its Cell Q systems across its facilities worldwide for Bristol Myers Squibb to produce CAR-T therapies clinically and commercially.
Facilities & Capacity
Higher yields, improved media, and perfusion are driving network optimization at Roche and led to the recent divestment of a 330,000 L California facility to CDMO Lonza.
Merck KGaA has begun construction on an 18,000 square-meter research center at its global headquarters in Darmstadt, Germany.
Global Markets
Sartorius has closed its first quarter positively “in line” with expectations but highlights China as a continued market weakness.
Regeneron has joined its fellow pharma players in the venture investing space by committing up to $500 million over five years across the healthcare industry.
Regulations
CDMO AGC Bio will supply lentiviral vectors for Orchard Therapeutics’ metachromatic leukodystrophy (MLD) gene therapy, approved in the US this week.
Global biopharma lobbying organization BIO has forced WuXi AppTec to leave the group due to pressure from the US Congress.
Therapeutic Class
With a roughly flat quarter in sales revenue, J&J said it will continue to expand capacity and cites Carvykti as a key driver for growth in 2024.
Africa Centres for Disease Controls (CDC) has accused Moderna of abandoning its commitment to building vaccine manufacturing capabilities in Africa after pausing plans for a plant in Kenya.
Upstream & Downstream Processing
Higher yields, improved media, and perfusion are driving network optimization at Roche and led to the recent divestment of a 330,000 L California facility to CDMO Lonza.
Nigel Titchener-Hooker, professor and dean of engineering at University College London, guided delegates at BioProcess International Europe in Vienna, Austria, on a tour through drug-development history.